Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:08:29 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



Q:KPTI - KARYOPHARM THERAPEUTICS INC - http://www.karyopharm.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
KPTI - Q0.71.01·1.210.11.080.303    3.775  0.617408:43:44May 0215 min RT 2¢

Recent Trades - All 3 today
Time ETExPriceChangeVolume
08:43:44Q1.08120.001210
08:43:31Q1.08060.000610
08:34:19Q1.120.04200
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-02 16:30U:KPTINews ReleaseKaryopharm to Report First Quarter 2024 Financial Results on May 8, 2024
2024-05-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-24 16:01U:KPTINews ReleaseKaryopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
2024-04-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-06 16:05U:KPTINews ReleaseKaryopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
2024-03-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-29 07:30U:KPTINews ReleaseKaryopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
2024-02-22 07:00U:KPTINews ReleaseKaryopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
2024-02-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-08 08:30U:KPTINews ReleaseKaryopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
2024-01-03 07:00U:KPTINews ReleaseKaryopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-10 20:15U:KPTINews ReleaseKaryopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Na ƒ ¯ve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(
2023-12-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-08 16:05U:KPTINews ReleaseKaryopharm to Participate at Upcoming Investor Conferences
2023-11-06 07:00U:KPTINews ReleaseKaryopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study
2023-11-02 09:20U:KPTINews ReleaseKaryopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)
2023-11-02 07:30U:KPTINews ReleaseKaryopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
2023-10-30 08:00U:KPTINews ReleaseKaryopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD ¢ „ ¢ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
2023-10-26 07:00U:KPTINews ReleaseKaryopharm to Report Third Quarter 2023 Financial Results on November 2, 2023